RSS   Newsletter   Contact   Advertise with us

Crescita Therapeutics Q2 revenue $1,733

Christian Fernsby ▼ | August 13, 2020
Crescita Therapeutics reported its financial results for the second quarter ended June 30, 2020.
Crescita Therapeutics
Crescita Therapeutics   Revenue was $1,733, a decrease of $7,629
Revenue was $1,733, a decrease of $7,629.

Topics: Crescita Therapeutics

In Q2-F2019, the Company recognized $5,459 in up-front payments and guaranteed future minimum royalties in connection with the out-licensing agreement with Cantabria Labs.

Gross profit was $1,092, Operating expenses (excluding COGS) were $2,318, a decrease of $1,012.

Adjusted EBITDA1 was $(781), a decrease of $5,864, mainly due to the revenue recognized in connection with the Cantabria Agreement in Q2-F2019 of $5,459.